Vistagen, Fuji Enter Exclusive Negotiation Agreement For Potential License To Develop, Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, In Japan; Vistagen To Receive $1.5M
Portfolio Pulse from Benzinga Newsdesk
Vistagen and Fuji have entered into an exclusive negotiation agreement for a potential license to develop and commercialize Vistagen's investigational menopausal hot flash therapy, PH80 Nasal Spray, in Japan. Vistagen will receive $1.5 million and Fuji will obtain a time-limited exclusive negotiation period for the Japanese market. A recent Phase 2A study showed PH80's significant reduction in the number of hot flashes and related symptoms compared with placebo.
September 05, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen's potential partnership with Fuji for the development and commercialization of PH80 Nasal Spray in Japan could provide a new revenue stream. The recent positive results from the Phase 2A study further increase the potential value of this deal.
The news of a potential partnership with Fuji for the development and commercialization of PH80 Nasal Spray in Japan is directly related to Vistagen and could have a positive impact on its stock price. The deal could open up a new revenue stream for Vistagen. Furthermore, the recent positive results from the Phase 2A study increase the potential value of this deal and could boost investor confidence in Vistagen.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100